- Alkermes reported an EPS of $0.29, missing the estimated $0.43.
- The company exceeded revenue expectations with $384.5 million reported.
- Alkermes has a P/E ratio of approximately 22.76 and a price-to-sales ratio of about 3.74.
Alkermes plc (NASDAQ:ALKS), a biopharmaceutical company, is known for its focus on developing innovative medicines for central nervous system disorders, addiction, and cancer. Competing with pharmaceutical giants, Alkermes strives to deliver effective treatments and maintain a strong market presence.
On February 25, 2026, Alkermes reported its earnings, revealing an earnings per share (EPS) of $0.29, which was below the estimated $0.43. Despite this shortfall, the company exceeded revenue expectations, reporting $384.5 million compared to the anticipated $381.5 million. This indicates a strong revenue performance, even though the EPS did not meet projections.
Alkermes has a price-to-earnings (P/E) ratio of approximately 22.76, which provides insight into how the market values its earnings. A P/E ratio is a measure of a company’s current share price relative to its per-share earnings. The company’s price-to-sales ratio is about 3.74, reflecting the market’s valuation of its revenue. This ratio helps investors understand how much they are paying for each dollar of the company’s sales.
The enterprise value to sales ratio for Alkermes is roughly 3.34, and the enterprise value to operating cash flow ratio is about 9.10. These metrics offer a broader view of the company’s valuation, taking into account its debt and cash reserves. The earnings yield for Alkermes is approximately 4.39%, indicating the earnings generated per dollar invested in the company’s stock. This yield can be a useful measure for investors assessing the potential return on their investment.
